Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

654
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
654
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

396
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
396
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

704
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
704
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

832
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
832
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perspectives on phenotype in genetic testing for early-onset atrial fibrillation.

European journal of human genetics : EJHG·2026
Same author

Beyond insulin escalation: REIMAGINE 3 and advanced type 2 diabetes care.

Lancet (London, England)·2026
Same author

Sex Differences in 6-Year Change in eGFR and ACR in a Multiethnic Population: The HELIUS Study.

Kidney medicine·2026
Same author

sncRNA levels predict SNORD105B is a novel biomarker of chronic kidney disease risk and SGLT2 inhibitor response in type 2 diabetes.

Molecular therapy. Nucleic acids·2026
Same author

Hyaluronan Regulates Vascular Smooth Muscle Cell Osteogenic Differentiation and Vascular Calcification.

Biomolecules·2026
Same author

Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial.

European journal of heart failure·2026

Related Experiment Video

Updated: May 13, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.2K

Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY).

Kennedy S Ramos1, Soufiane Nassiri2, Leonoor F J Wijdeveld3

  • 1Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands. k.silvaramos@amsterdamumc.nl.

Cardiovascular Drugs and Therapy
|April 14, 2025
PubMed
Summary

This study investigates if Geranylgeranylacetone (GGA) can prevent postoperative atrial fibrillation (PoAF) in heart surgery patients. Results are expected to show GGA

Keywords:
Cardiothoracic surgeryHeat shock proteinsPostoperative atrial fibrillationPrevention

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.3K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.6K

Related Experiment Videos

Last Updated: May 13, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.3K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.6K

Area of Science:

  • Cardiology and Cardiac Surgery
  • Pharmacology and Therapeutics
  • Biomedical Research

Background:

  • Postoperative atrial fibrillation (PoAF) affects 30-50% of patients after cardiothoracic surgery.
  • Current preventive therapies for PoAF remain suboptimal.
  • Previous research indicated Geranylgeranylacetone (GGA) enhances cardioprotective heat shock proteins (HSPs).

Purpose of the Study:

  • To evaluate the efficacy of oral Geranylgeranylacetone (GGA) in preventing PoAF.
  • To assess GGA's potential to reduce AF incidence in patients undergoing elective cardiothoracic surgery.

Main Methods:

  • A phase II, single-center, double-blind, placebo-controlled randomized trial (GENIALITY study).
  • 146 adult patients undergoing elective open-heart surgery received either 300 mg GGA or placebo daily.
  • Treatment initiated 5 days pre-surgery to 3 days post-surgery, with Holter monitoring until discharge.

Main Results:

  • Primary endpoint: Comparison of PoAF incidence between the GGA and placebo groups.
  • Secondary endpoints: Assessment of heat shock protein (HSP) levels via biochemical analysis.
  • Analysis of proteostasis markers in blood, atrial appendage, and epicardial adipose tissue.

Conclusions:

  • The study aims to demonstrate a reduction in PoAF incidence with GGA treatment.
  • Expected to provide proof of concept for GGA's beneficial role in preventing PoAF.
  • Potential to establish GGA as a novel therapeutic strategy for cardiothoracic surgery patients.